Comprehensive Genomic Profiling of Androgen-Receptor-Negative Canine Prostate Cancer
Abstract
:1. Introduction
2. Results
2.1. Genomic Analysis
2.2. Transcript Expression Levels
3. Discussion
4. Materials and Methods
4.1. Ethics Statement
4.2. Patients
4.3. Chromosomal Imbalances Analysis (aCGH)
4.4. Gene Expression Analysis
4.5. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Abbreviations
PC | Prostate cancer |
PIA | Proliferative inflammatory atrophy |
CNAs | Copy number alterations |
TCGA | The Cancer Genome Atlas |
CGH | Comparative genomic hybridization |
aCGH | Array-based comparative genomic hybridization |
IHC | Immunohistochemistry |
IPA | Ingenuity Pathway Analysis |
PIN | Prostatic intraepithelial neoplasia |
References
- Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108. [Google Scholar] [CrossRef] [PubMed]
- Bostwick, D.G.; Qian, J. High-grade prostatic intraepithelial neoplasia. Mod. Pathol. 2004, 17, 360–379. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leroy, B.E.; Northrup, N. Prostate cancer in dogs: Comparative and clinical aspects. Vet. J. 2009, 180, 149–162. [Google Scholar] [CrossRef] [PubMed]
- Matsuzaki, P.; Cogliati, B.; Sanches, D.S.; Chaible, L.M.; Kimura, K.C.; Silva, T.C.; Real-Lima, M.A.; Hernandez-Blazquez, F.J.; Laufer-Amorim, R.; Dagli, M.L. Immunohistochemical characterization of canine prostatic intraepithelial neoplasia. J. Comp. Pathol. 2010, 142, 84–88. [Google Scholar] [CrossRef] [PubMed]
- Fonseca-Alves, C.E.; Rodrigues, M.M.; de Moura, V.M.; Rogatto, S.R.; Laufer-Amorim, R. Alterations of C-MYC, NKX3.1, and E-cadherin expression in canine prostate carcinogenesis. Microsc. Res. Tech. 2013, 76, 1250–1256. [Google Scholar] [CrossRef] [PubMed]
- Romanucci, M.; Frattone, L.; Ciccarelli, A.; Bongiovanni, L.; Malatesta, D.; Benazzi, C.; Brachelente, C.; Della Salda, L. Immunohistochemical expression of heat shock proteins, p63 and androgen receptor in benign prostatic hyperplasia and prostatic carcinoma in the dog. Vet. Comp. Oncol. 2016, 14, 337–349. [Google Scholar] [CrossRef]
- Fonseca-Alves, C.E.; Kobayashi, P.E.; Calderón, L.G.R.; Felisbino, S.L.; Rinaldi, J.C.; Drigo, S.A.; Rogatto, S.R.; Laufer-Amorim, R. Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression. PLoS ONE 2018, 13, e0199173. [Google Scholar] [CrossRef] [PubMed]
- McNeal, J.E.; Redwine, E.A.; Freiha, F.S.; Stamey, T.A. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am. J. Surg. Pathol. 1988, 12, 897–906. [Google Scholar] [CrossRef] [PubMed]
- Leroy, C.; Conchou, F.; Layssol-Lamour, C.; Deviers, A.; Sautet, J.; Concordet, D.; Mogicato, G. Normal canine prostate gland: Repeatability, reproducibility, observer-dependent variability of ultrasonographic measurements of the prostate in healthy intact beagles. Anat. Histol. Embryol. 2013, 42, 355–361. [Google Scholar] [CrossRef]
- Fonseca-Alves, C.E.; Kobayashi, P.E.; Rivera-Calderón, L.G.; Laufer-Amorim, R. Evidence of epithelial-mesenchymal transition in canine prostate cancer metastasis. Res. Vet. Sci. 2015, 100, 176–181. [Google Scholar] [CrossRef]
- Rivera-Calderón, L.G.; Fonseca-Alves, C.E.; Kobayashi, P.E.; Carvalho, M.; Drigo, S.A.; de Oliveira Vasconcelos, R.; Laufer-Amorim, R. Alterations in PTEN, MDM2, TP53 and AR protein and gene expression are associated with canine prostate carcinogenesis. Res. Vet. Sci. 2016, 106, 56–61. [Google Scholar] [CrossRef] [PubMed]
- Abate-Shen, C.; Banach-Petrosky, W.A.; Sun, X.; Economides, K.D.; Desai, N.; Gregg, J.P.; Borowsky, A.D.; Cardiff, R.D.; Shen, M.M. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 2003, 63, 3886–3890. [Google Scholar] [PubMed]
- DeMarzo, A.M.; Nelson, W.G.; Isaacs, W.B.; Epstein, J.I. Pathological and molecular aspects of prostate cancer. Lancet 2003, 361, 955–964. [Google Scholar] [CrossRef]
- Akter, S.H.; Lean, F.Z.; Lu, J.; Grieco, V.; Palmieri, C. Different Growth Patterns of Canine Prostatic Carcinoma Suggests Different Models of Tumor-Initiating Cells. Vet. Pathol. 2015, 52, 1027–1033. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palmieri, C.; Lean, F.Z.; Akter, S.H.; Romussi, S.; Grieco, V. A retrospective analysis of 111 canine prostatic samples: Histopathological findings and classification. Res. Vet. Sci. 2014, 97, 568–573. [Google Scholar] [CrossRef] [PubMed]
- Schiffman, J.D.; Breen, M. Comparative oncology: What dogs and other species can teach us about humans with cancer. Philos. Trans. R. Soc. 2015, 370, 20140231. [Google Scholar] [CrossRef] [PubMed]
- Kobayashi, P.E.; Fonseca-Alves, C.E.; Rivera-Calderón, L.G.; Carvalho, M.; Kuasne, H.; Rogatto, S.R.; Laufer-Amorim, R. Deregulation of E-cadherin, β-catenin, APC and Caveolin-1 expression occurs in canine prostate cancer and metastatic processes. Res. Vet. Sci. 2018, 118, 254–261. [Google Scholar] [CrossRef]
- Dunn, K.A.; Thomas, R.; Binns, M.M.; Breen, M. Comparative genomic hybridization (CGH) in dogs—Application to the study of a canine glial tumour cell line. Vet. J. 2000, 160, 77–82. [Google Scholar] [CrossRef]
- Thomas, R.; Smith, K.C.; Ostrander, E.A.; Galibert, F.; Breen, M. Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridization and a panel of single locus probes. Br. J. Cancer 2003, 89, 1530–1537. [Google Scholar] [CrossRef]
- Thomas, R.; Rebbeck, C.; Leroi, A.M.; Burt, A.; Breen, M. Extensive conservation of genomic imbalances in canine transmissible venereal tumors (CTVT) detected by microarray-based CGH analysis. Chromosome Res. 2009, 17, 927–934. [Google Scholar] [CrossRef]
- Tsai, P.C.; Breen, M. Array-based comparative genomic hybridization-guided identification of reference genes for normalization of real-time quantitative polymerase chain reaction assay data for lymphomas, histiocytic sarcomas, and osteosarcomas of dogs. Am. J. Vet. Res. 2012, 73, 1335–1343. [Google Scholar] [CrossRef] [PubMed]
- Poorman, K.; Borst, L.; Moroff, S.; Roy, S.; Labelle, P.; Motsinger-Reif, A.; Breen, M. Comparative cytogenetic characterization of primary canine melanocytic lesions using array CGH and fluorescence in situ hybridization. Chromosome Res. 2015, 23, 171–186. [Google Scholar] [CrossRef]
- Simmons, J.K.; Dirksen, W.P.; Hildreth, B.E., 3rd; Dorr, C.; Williams, C.; Thomas, R.; Breen, M.; Toribio, R.E.; Rosol, T.J. Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo. Prostate 2014, 74, 1251–1265. [Google Scholar] [CrossRef]
- Hernandez, B.; Adissu, H.A.; Wei, B.R.; Michael, H.T.; Merlino, G.; Simpson, R.M. Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas. Int. J. Mol. Sci. 2018, 19, 394. [Google Scholar] [CrossRef] [PubMed]
- Canto, P.; Granados, J.B.; Feria-Bernal, G.; Coral-Vázquez, R.M.; García-García, E.; Tejeda, M.E.; Tapia, A.; Rojano-Mejía, D.; Méndez, J.P. PPARGC1A and ADIPOQ polymorphisms are associated with aggressive prostate cancer in Mexican-Mestizo men with overweight or obesity. Cancer Biomark. 2017, 19, 297–303. [Google Scholar] [CrossRef]
- Dmitriev, A.A.; Rosenberg, E.E.; Krasnov, G.S.; Gerashchenko, G.V.; Gordiyuk, V.V.; Pavlova, T.V.; Kudryavtseva, A.V.; Beniaminov, A.D.; Belova, A.A.; Bondarenko, Y.N.; et al. Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis. Dis. Markers 2015, 2015, 241301. [Google Scholar] [CrossRef] [PubMed]
- Ashida, S.; Nakagawa, H.; Katagiri, T.; Furihata, M.; Iiizumi, M.; Anazawa, Y.; Tsunoda, T.; Takata, R.; Kasahara, K.; Miki, T.; et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: Genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res. 2004, 64, 5963–5972. [Google Scholar] [CrossRef] [PubMed]
- Yildiz-Sezer, S.; Verdorfer, I.; Schafer, G.; Rogatsch, H.; Bartsch, G.; Mikuz, G. Assessment of aberrations on chromosome 8 in prostatic atrophy. BJU Int. 2006, 98, 184–188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cher, M.L.; MacGrogan, D.; Bookstein, R.; Brown, J.A.; Jenkins, R.B.; Jensen, R.H. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 1994, 11, 153–162. [Google Scholar] [CrossRef] [PubMed]
- Cree, I.A.; Glaysher, S.; Harvey, A.L. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr. Opin. Pharmacol. 2010, 10, 375–379. [Google Scholar] [CrossRef] [PubMed]
- Baskaran, S.; Mayrhofer, M.; Kultima, H.G.; Bergström, T.; Elfineh, L.; Cavelier, L.; Isaksson, A.; Nelander, S. Primary glioblastoma cells for precision medicine: A quantitative portrait of genomic (in)stability during the first 30 passages. Neuro Oncol. 2018, 20, 1080–1091. [Google Scholar] [CrossRef] [PubMed]
- Schoenborn, J.R.; Nelson, P.; Fang, M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin. Cancer Res. 2013, 19, 4058–4066. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Williams, J.L.; Greer, P.A.; Squire, J.A. Recurrent copy number alterations in prostate cancer: An in silico meta-analysis of publicly available genomic data. Cancer Genet. 2014, 207, 474–488. [Google Scholar] [CrossRef] [PubMed]
- Liu, W. DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. Asian J. Androl. 2016, 18, 533–542. [Google Scholar] [CrossRef] [PubMed]
- Fraser, M.; Sabelnykova, V.Y.; Yamaguchi, T.N.; Heisler, L.E.; Livingstone, J.; Huang, V.; Shiah, Y.J.; Yousif, F.; Lin, X.; Masella, A.P.; et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 2017, 541, 359–364. [Google Scholar] [CrossRef] [PubMed]
- Seipel, A.H.; Whitington, T.; Delahunt, B.; Samaratunga, H.; Mayrhofer, M.; Wiklund, P.; Grönberg, H.; Lindberg, J.; Egevad, L. Genetic profile of ductal adenocarcinoma of the prostate. Hum. Pathol. 2017, 69, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Wei, B.; Jin, J.P. TNNT1, TNNT2, and TNNT3: Isoform genes, regulation, and structure-function relationships. Gene 2016, 582, 1–13. [Google Scholar] [CrossRef]
- Urbanucci, A.; Barfeld, S.J.; Kytölä, V.; Itkonen, H.M.; Coleman, I.M.; Vodák, D.; Sjöblom, L.; Sheng, X.; Tolonen, T.; Minner, S.; et al. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep. 2017, 19, 2045–2059. [Google Scholar] [CrossRef] [Green Version]
- Bettuzzi, S.; Davalli, P.; Davoli, S.; Chayka, O.; Rizzi, F.; Belloni, L.; Pellacani, D.; Fregni, G.; Astancolle, S.; Fassan, M.; et al. Genetic inactivation of ApoJ/clusterin: Effects on prostate tumourigenesis and metastatic spread. Oncogene 2009, 28, 4344–4352. [Google Scholar] [CrossRef]
- Rizzi, F.; Bettuzzi, S. Clusterin (CLU) and prostate cancer. Adv. Cancer Res. 2009, 105, 1–19. [Google Scholar]
- Brown, S.G.; Knowell, A.E.; Hunt, A.; Patel, D.; Bhosle, S.; Chaudhary, J. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis. Prostate 2015, 75, 266–279. [Google Scholar] [CrossRef] [PubMed]
- Yang, W.S.; Chadalapaka, G.; Cho, S.G.; Lee, S.O.; Jin, U.H.; Jutooru, I.; Choi, K.; Leung, Y.K.; Ho, S.M.; Safe, S.; et al. The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis. Neoplasia 2014, 16, 1059–1069. [Google Scholar] [CrossRef]
- Roussel-Gervais, A.; Naciri, I.; Kirsh, O.; Kasprzyk, L.; Velasco, G.; Grillo, G.; Dubus, P.; Defossez, P.A. Loss of the Methyl-CpG-Binding Protein ZBTB4 Alters Mitotic Checkpoint, Increases Aneuploidy, and Promotes Tumorigenesis. Cancer Res. 2017, 77, 62–73. [Google Scholar] [CrossRef] [PubMed]
- Kim, K.; Chadalapaka, G.; Pathi, S.S.; Jin, U.H.; Lee, J.S.; Park, Y.Y.; Cho, S.G.; Chintharlapalli, S.; Safe, S. Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters. Mol. Cancer Ther. 2012, 11, 1852–1862. [Google Scholar] [CrossRef] [PubMed]
- Li, C.; Liu, S.; Yan, R.; Han, N.; Wong, K.K.; Li, L. CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. Theranostics 2017, 7, 67–80. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chan, J.J.; Kwok, Z.H.; Chew, X.H.; Zhang, B.; Liu, C.; Soong, T.W.; Yang, H.; Tay, Y. A FTH1 gene:pseudogene:microRNA network regulates tumorigenesis in prostate cancer. Nucleic Acids Res. 2018, 46, 1998–2011. [Google Scholar] [CrossRef] [PubMed]
- Martin, P.; Liu, Y.N.; Pierce, R.; Abou-Kheir, W.; Casey, O.; Seng, V.; Camacho, D.; Simpson, R.M.; Kelly, K. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am. J. Pathol. 2011, 179, 422–435. [Google Scholar] [CrossRef] [PubMed]
- Venkatesan, T.; Alaseem, A.; Chinnaiyan, A.; Dhandayuthapani, S.; Kanagasabai, T.; Alhazzani, K.; Dondapati, P.; Alobid, S.; Natarajan, U.; Schwartz, R.; et al. MDM2 Overexpression Modulates the Angiogenesis-Related Gene Expression Profile of Prostate Cancer Cells. Cells 2018, 7, 41. [Google Scholar] [CrossRef] [PubMed]
- Kwon, M.J.; Min, S.K.; Seo, J.; Kim, D.H.; Sung, C.O.; Lim, M.S.; Cho, J.; Park, H.R. HIPK2 expression in progression of cutaneous epithelial neoplasm. Int. J. Dermatol. 2015, 54, 347–354. [Google Scholar] [CrossRef] [PubMed]
- Ann, E.J.; Kim, M.Y.; Yoon, J.H.; Ahn, J.S.; Jo, E.H.; Lee, H.J.; Lee, H.W.; Kang, H.G.; Choi, D.W.; Chun, K.H.; et al. Tumor Suppressor HIPK2 Regulates Malignant Growth via Phosphorylation of Notch1. Cancer Res. 2016, 76, 4728–4740. [Google Scholar] [CrossRef] [PubMed]
- Lonergan, P.E.; Tindall, D.J. Androgen receptor signaling in prostate cancer development and progression. J. Carcinog. 2011, 10, 20. [Google Scholar] [PubMed]
- Tan, M.H.; Li, J.; Xu, H.E.; Melcher, K.; Yong, E.L. Androgen receptor: Structure, role in prostate cancer and drug discovery. Acta Pharmacol. Sin. 2015, 36, 3–23. [Google Scholar] [CrossRef] [PubMed]
- Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997, 57, 314–319. [Google Scholar] [PubMed]
- Huang, Y.; Jiang, X.; Liang, X.; Jiang, G. Molecular and cellular mechanisms of castration resistant prostate cancer. Oncol. Lett. 2018, 15, 6063–6076. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leav, I.; Schelling, K.H.; Adams, J.Y.; Merk, F.B.; Alroy, J. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma. Prostate 2001, 48, 210–224. [Google Scholar] [CrossRef] [PubMed]
- Lai, C.L.; van den Ham, R.; van Leenders, G.; van der Lugt, J.; Mol, J.A.; Teske, E. Histopathological and immunohistochemical characterization of canine prostate cancer. Prostate 2008, 68, 477–488. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, J.; Hong, W.Y.; Cho, M.; Sim, M.; Lee, D.; Ko, Y.; Kim, J. Synteny Portal: A web-based application portal for synteny block analysis. Nucleic Acid Res. 2016, 44, W35–W40. [Google Scholar]
- Larsen, S.J.; do Canto, L.M.; Rogatto, S.R.; Baumbach, J. CoNVaQ: A web tool for copy number variation-based association studies. BMC Genom. 2018, 19, 369. [Google Scholar] [CrossRef]
- Hu, Y.; Yan, C.; Hsu, C.H.; Chen, Q.R.; Niu, K.; Komatsoulis, G.A.; Meerzaman, D. OmicCircos: A Simple-to-Use R Package for the Circular Visualization of Multidimensional Omics Data. Cancer Inform. 2014, 13, 13–20. [Google Scholar] [CrossRef]
- Fonseca-Alves, C.E.; Kobayashi, P.E.; Laufer-Amorim, R. Evaluation of NKX3.1 and C-MYC expression in canine prostatic cancer. Res. Vet. Sci. 2018, 118, 365–370. [Google Scholar] [CrossRef]
- Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef] [PubMed]
COPY NUMBER LOSSES | |||||
---|---|---|---|---|---|
Gene | Canine PC (N = 14) | Human PC TCGA (N = 492) | Gene | Canine PC (N = 14) | Human PC TCGA (N = 492) |
ACTB | 4 | 7 | MTPN | 3 | 12 |
ADRA1A | 3 | 275 | MX1 | 5 | 134 |
AZGP1 | 4 | 7 | MX2 | 5 | 130 |
CASP2 | 3 | 11 | MYH1 | 4 | 110 |
CCL17 | 3 | 123 | MYH2 | 3 | 110 |
CCL24 | 4 | 5 | MYH3 | 3 | 109 |
CCL26 | 4 | 3 | MYH4 | 4 | 110 |
CDH1 | 3 | 143 | MYH8 | 4 | 110 |
CFDP1 | 3 | 187 | NIP7 | 3 | 146 |
CHST4 | 3 | 169 | NOS3 | 3 | 12 |
CLCN1 | 3 | 11 | OCLN | 2 | 102 |
CLDN3 | 4 | 3 | PDGFA | 4 | 13 |
CLU | 3 | 268 | PLA2G15 | 3 | 136 |
CNGB1 | 3 | 118 | POR | 4 | 4 |
CX3CL1 | 3 | 123 | RAC1 | 4 | 7 |
CYBA | 3 | 192 | RCVRN | 3 | 110 |
EIF2AK1 | 4 | 7 | RPL26 | 3 | 119 |
EIF4A1 | 3 | 159 | SERPINE1 | 4 | 10 |
EPO | 4 | 6 | SLC12A4 | 3 | 132 |
FAM83H | 8 | 12 | SLC2A4 | 3 | 155 |
FASTK | 3 | 12 | SLC4A1 | 3 | 96 |
GALNS | 3 | 192 | SLC7A5 | 3 | 202 |
GP1BA | 3 | 103 | SSBP1 | 3 | 9 |
GUCY2D | 3 | 153 | SSPO | 3 | 10 |
HIPK2 | 3 | 10 | TAS2R3 | 3 | 9 |
HSF4 | 4 | 130 | TAS2R38 | 3 | 12 |
HSPB1 | 3 | 3 | TAS2R39 | 3 | 11 |
KCNH2 | 3 | 12 | TAS2R40 | 3 | 11 |
LUC7L2 | 3 | 9 | TAS2R41 | 3 | 10 |
MC1R | 3 | 188 | TAS2R5 | 3 | 9 |
MIR106B | 4 | 7 | TEKT1 | 3 | 131 |
MIR140 | 3 | 152 | TNFSF12 | 3 | 159 |
MIR25 | 4 | 7 | TNFSF13 | 3 | 159 |
MIR324 | 3 | 149 | TP53 | 3 | 163 |
MIR328 | 3 | 130 | TRPV1 | 3 | 93 |
MIR490 | 3 | 10 | WWP2 | 3 | 153 |
MIR589 | 4 | 7 | ZBTB4 | 3 | 158 |
MIR590 | 4 | 4 | ZNF252 | 4 | 13 |
MIR671 | 3 | 12 | ZP3 | 3 | 5 |
MIR93 | 4 | 7 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Laufer-Amorim, R.; Fonseca-Alves, C.E.; Villacis, R.A.R.; Linde, S.A.D.; Carvalho, M.; Larsen, S.J.; Marchi, F.A.; Rogatto, S.R. Comprehensive Genomic Profiling of Androgen-Receptor-Negative Canine Prostate Cancer. Int. J. Mol. Sci. 2019, 20, 1555. https://doi.org/10.3390/ijms20071555
Laufer-Amorim R, Fonseca-Alves CE, Villacis RAR, Linde SAD, Carvalho M, Larsen SJ, Marchi FA, Rogatto SR. Comprehensive Genomic Profiling of Androgen-Receptor-Negative Canine Prostate Cancer. International Journal of Molecular Sciences. 2019; 20(7):1555. https://doi.org/10.3390/ijms20071555
Chicago/Turabian StyleLaufer-Amorim, Renée, Carlos Eduardo Fonseca-Alves, Rolando Andre Rios Villacis, Sandra Aparecida Drigo Linde, Marcio Carvalho, Simon Jonas Larsen, Fabio Albuquerque Marchi, and Silvia Regina Rogatto. 2019. "Comprehensive Genomic Profiling of Androgen-Receptor-Negative Canine Prostate Cancer" International Journal of Molecular Sciences 20, no. 7: 1555. https://doi.org/10.3390/ijms20071555